Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 2Solid Tumors 1Pancreatic Adenocarcinoma 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced/Metastatic Solid Tumors 1

Interventions

Paclitaxel 12atezolizumab 11Gemcitabine 9pembrolizumab 8Injections 6Carboplatin 6Irinotecan 5Docetaxel 5Cetuximab 5tocilizumab 4navitoclax 4Leucovorin 4Fluorouracil 4Bevacizumab 4olaparib 3cobimetinib 3Oxaliplatin 3Nivolumab 3zolbetuximab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2tivozanib 2tislelizumab 2spartalizumab 2ridaforolimus 2plocabulin 2obinutuzumab 2motesanib diphosphate 2liposomal doxorubicin 2linifanib 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumors × selicrelumab × Clear all
NCT02304393 2019-12-13

A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
140 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡